<DOC>
	<DOCNO>NCT01499082</DOCNO>
	<brief_summary>Primary Objective : - To compare efficacy insulin glargine new formulation Lantus term change HbA1c baseline endpoint ( schedule month 6 ) adult participant type 2 diabetes mellitus Secondary Objectives : - To compare efficacy insulin glargine new formulation Lantus term occurrence nocturnal Hypoglycemia</brief_summary>
	<brief_title>Comparison New Formulation Insulin Glargine With Lantus Patients With Type 2 Diabetes Mellitus Basal Plus Mealtime Insulin</brief_title>
	<detailed_description>The maximum study duration approximately 58 week per participant , consist : - 2 week screen period - 6-month comparative efficacy safety treatment period - 6-month comparative safety extension period - 4-week safety follow-up period subset participant - 3-month administration substudy period start completion 6-month study period participant willing subset participant randomize HOE901-U300</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Participants type 2 diabetes mellitus Substudy inclusion criterion : Completion 6month study period main study ( Visit 10 ) Randomized treated insulin glargine new formulation 6month treatment period ( Baseline month 6 ) Exclusion criterion : Age le ( &lt; ) 18 year HbA1c &lt; 7.0 % great ( &gt; ) 10 % screen Diabetes type 2 diabetes mellitus Less 1 year basal plus mealtime insulin selfmonitoring blood glucose Any contraindication use insulin glargine define national product label Participants use human regular insulin mealtime insulin last 3 month screen visit Use insulin pump last 6 month screen visit Initiation new glucoselowering agent and/or weight loss drug last 3 month screen visit History presence significant diabetic retinopathy macular edema likely require laser injectable drug surgical treatment study period Pregnant breastfeed woman woman intend become pregnant study period Substudy exclusion criterion : Participant willing use adaptable injection interval least two day per week The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>